Puma Biotechnology, Inc. (PBYI) NASDAQ

6.98

-0.14(-1.97%)

Updated at June 02 04:00PM

Currency In USD

Puma Biotechnology, Inc.

Address

10880 Wilshire Boulevard

Los Angeles, CA 90024

United States of America (the)

Phone

424 248 6500

Sector

Healthcare

Industry

Biotechnology

Employees

172

First IPO Date

April 24, 2012

Key Executives

NameTitlePayYear Born
Alan H. AuerbachFounder, Chairman, President, Chief Executive Officer & Secretary1.98M1970
Douglas Hunt FRAPSChief Regulatory Affairs, Medical Affairs, Pharmacovigilance & Law Officer797,7571965
Maximo F. NouguesChief Financial Officer & Principal Accounting Officer904,4861969
Petra RietschelSenior Vice President of Clinical Development0N/A
Gordon G. EsplinChief Accounting Officer01968
Kenneth WieheSenior Vice President of Supply Chain & Manufacturing0N/A
Heather BlaberSenior Vice President of Marketing0N/A
Pamela WilsonSenior Vice President of Clinical Operations0N/A
Mariann OhanesianSenior Director of Investor Relations0N/A
Roger L. StormsSenior Vice President of Sales0N/A

Description

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.